In experimental autoimmune myositis, the treatment with anti-CX3CL1 antibody reduced the numbers of muscle infiltrating cells and ameliorated histological inflammatory lesions pointing to the potential therapeutic role of CX3CL1 inhibition and/or CX3CL1/CX3CR1 block in the treatment of RA and inflammatory myopathies [28]. The gene discussed is CX3CR1; the disease is rheumatoid arthritis.